Point mutation of c-Ha-ras oncogene in oral cancers
Liu, X.F.
Zhonghua Kou Qiang Yi Xue Za Zhi 26(6): 326-328; 388
1991
ISSN/ISBN: 1002-0098 PMID: 1820236 Document Number: 385832
After sub-sequence of c-Ha-ras oncogene in 11 Chinese oral cancers was amplified with in vitro DNA amplification technique, G----T mutation of c-Ha-ras oncogene at codon 12 was detected by specific mutated oligonucleotide probe, resulting in point mutation of c-Ha-ras oncogene at codon 12 in 4 out of 11 oral cancers which shows that c-Ha-ras oncogene is one of the genes associated with the development and progression of oral cancers, and point mutation may lead to activation of c-Ha-ras oncogene.
Document emailed within 1 workday
Related Documents
Zhou, Z.; Tang, G.; Zhong, W. 2000: Experimental study on the influence of Gynostemma pentaphyllam Mak upon point mutation of Ha-ras oncogene in blocking leukoplakia from canceration Zhonghua Kou Qiang Yi Xue Za Zhi 35(2): 91-94Chewawiwat, N.; Lulitanond, V.; Nimmanahaeminda, K.; Thamprasert, K.; Nicomrat, D.; Ponglikitmongkol, M. 1995: Use of PCR-PIRA for screening of a point mutation at codon 12 in K-ras oncogene obtained from paraffin embedded tissue sections Southeast Asian Journal of Tropical Medicine and Public Health 26(Suppl 1): 329-332
Nakasato, F.; Sakamoto, H.; Mori, M.; Hayashi, K.; Shimosato, Y.; Nishi, M.; Takao, S.; Nakatani, K.; Terada, M.; Sugimura, T. 1984: Amplification of the c-myc oncogene in human stomach cancers Gan 75(9): 737-742
Rosenblatt, K.A.; Gao, D.L.; Ray, R.M.; Nelson, Z.C.; Wernli, K.J.; Li, W.; Thomas, D.B. 2009: Oral contraceptives and the risk of all cancers combined and site-specific cancers in Shanghai Cancer Causes and Control: Ccc 20(1): 27-34
Mazura, I.; Vcelák, J.; Bendlová, B.; Neradilová, M.; Nĕmec, J.; Stolba, P. 1996: Ret proto-oncogene mutation found in the Czech population and its predictive value for offspring of patients with medullary carcinoma of the thyroid gland Vnitrni Lekarstvi 42(11): 751-756
Sypecka, J.; Domańska-Janik, K. 2006: Phenotypic diversity resulting from a point mutation Folia Neuropathologica 44(4): 244-250
Zhao, J.-q.; Guo, L.; Qi, X.-p.; Chen, Z.-g.; Wang, K.-j.; Lou, J.-l.; Yu, X.-h.; Cheng, J.; Jin, H.-y.; Li, X.-l.; Ying, R.-b.; Zhang, X.-n. 2013: Clinical diagnosis and treatment of familial medullary thyroid carcinoma caused by a p.C618Y RET proto-oncogene mutation in a Chinese pedigree Zhonghua Yi Xue Za Zhi 93(6): 440-444
Eng, C.; Clayton, D.; Schuffenecker, I.; Lenoir, G.; Cote, G.; Gagel, R.F.; van Amstel, H.K.; Lips, C.J.; Nishisho, I.; Takai, S.I.; Marsh, D.J.; Robinson, B.G.; Frank-Raue, K.; Raue, F.; Xue, F.; Noll, W.W.; Romei, C.; Pacini, F.; Fink, M.; Niederle, B.; Zedenius, J.; Nordenskjöld, M.; Komminoth, P.; Hendy, G.N.; Mulligan, L.M. 1996: The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis JAMA 276(19): 1575-1579
Goh, H.S.; Yao, J.; Smith, D.R. 1995: p53 point mutation and survival in colorectal cancer patients Cancer Research 55(22): 5217-5221
Sugio, K.; Fukuyama, Y.; Sakada, T.; Nishioka, K.; Yamazaki, K.; Ushijima, C.; Tsukamoto, S.; Ishida, T.; Sugimachi, K. 1998: Second primary cancers after resection of lung adenocarcinoma with ras gene mutation Anticancer Research 18(5a): 3395-3398
Deng, G.R. 1989: Relation of c-Ha-ras point mutation to the prognosis and metastasis of gastric carcinoma Zhonghua Yi Xue Za Zhi 69(8): 438
Nagata, Y.; Shiku, H. 1990: Dot hybridization with synthetic oligonucleotide; analysis of point mutation of c-ras genes Nihon Rinsho. Japanese Journal of Clinical Medicine 48(8): 163-169
Ries, J.C.; Schreiner, D.; Steininger, H.; Girod, S.C. 1998: p53 mutation and detection of p53 protein expression in oral leukoplakia and oral squamous cell carcinoma Anticancer Research 18(3b): 2031-2036
Kalinin, V.N.; Schmidt, W.; Poller, W.; Olek, K. 1995: A new point mutation in the mitochondrial gene ND1, detected in a patient with type Ii diabetes Genetika 31(8): 1180-1182
Igaki, H.; Sasaki, H.; Tachimori, Y.; Kato, H.; Watanabe, H.; Kimura, T.; Harada, Y.; Sugimura, T.; Terada, M. 1995: Mutation frequency of the p16/CDKN2 gene in primary cancers in the upper digestive tract Cancer Research 55(15): 3421-3423
Cairns, P.; Okami, K.; King, P.; Bonacum, J.; Ahrendt, S.; Wu, L.; Mao, L.; Jen, J.; Sidransky, D. 1997: Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions Cancer Research 57(23): 5356-5359
Høie, J.; Heimdal, K.; Nesland, J.M.; Børmer, O. 2000: Prophylactic thyroidectomy in carriers of RET oncogene mutation carriers Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 120(27): 3249-3252
Bratosiewicz, J.; Barcikowska, M.; Cervenakowa, L.; Brown, P.; Gajdusek, D.C.; Liberski, P.P. 2000: A new point mutation of the PRNP gene in Gerstmann-Sträussler-Scheinker case in Poland Folia Neuropathologica 38(4): 164-166
Ionasescu, V.V.; Hart, M.; DiMauro, S.; Moraes, C.T. 1994: Clinical and morphologic features of a myopathy associated with a point mutation in the mitochondrial tRNA(Pro) gene Neurology 44(5): 975-977
Kong, C.; Liu, T.; Zhang, M. 1996: Clinical importance of p53 gene mutation and PCNA expression in ureteral and renal pelvic cancers Zhonghua Zhong Liu Za Zhi 18(6): 436-438